Osteochondral Defect: Causes, Diagnosis, and Treatment

An osteochondral defect is an area of damage that extends through both the smooth cartilage lining a joint surface and the bone directly beneath it. These injuries matter because that two-layer structure, cartilage sitting on top of a thin plate of subchondral bone, works as a unit: the cartilage absorbs and distributes compressive forces while the bone underneath provides structural support. When one layer is injured, the other tends to follow. Because cartilage has almost no blood supply of its own, healing is slow and often incomplete, which is why osteochondral defects can cause persistent pain and, left unaddressed, accelerate joint degeneration.

How Cartilage and Bone Work Together

The joint surface is not a single material but a layered composite. Articular cartilage on top is tough yet flexible, and beneath it sits a thin plate of dense subchondral bone, followed by the spongy trabecular bone deeper inside. Together these layers are often called the osteochondral unit. Damage to the bone layer alters the way forces spread across the joint, which can trigger cartilage breakdown through abnormal loading. The reverse also happens: cartilage damage exposes the bone to forces it was never meant to absorb directly, prompting remodeling and the formation of cysts or sclerotic patches.¹

Research increasingly shows that the two tissues also communicate biochemically, exchanging signaling molecules through tiny channels in the subchondral plate. This biochemical crosstalk means that a problem originating in one layer can quietly spread to the other before any symptoms appear.² That interplay is one reason osteochondral defects are harder to treat than purely cartilage injuries: you cannot fix one layer in isolation and expect the joint to function normally.³

What Causes Osteochondral Defects

The most common cause is trauma. A sudden twisting injury, a bad landing from a jump, or a direct blow to the joint can damage the cartilage and bone simultaneously. The mechanical insult typically takes one of three forms: compaction (crushing force driven straight into the surface), shearing (a sideways force that peels cartilage away), or avulsion (where a fragment is torn off by a ligament or tendon pulling on it).⁴ Ankle sprains and knee ligament injuries are classic scenarios; in the ankle, the talus bone is a frequent site because of how it gets trapped and compressed during a twist.

Not all osteochondral defects start with a single obvious injury. A related condition called osteochondritis dissecans, or OCD, appears to develop more gradually, driven by repetitive microtrauma, impaired blood flow to the subchondral bone, or both. A systematic review of the research found that subchondral bone fracture and localized loss of blood supply (ischemia) are the events most consistently linked to OCD formation.⁵ Young athletes are particularly susceptible. A study of 126 elbows in patients aged 8 to 18 found that the type of sport influenced where lesions appeared: gymnasts tended to develop more posteriorly located lesions and had the highest rate of bilateral involvement, while every unilateral elbow lesion in baseball players occurred in the dominant throwing arm.⁶

Symptoms and When to Suspect a Problem

The frustrating reality is that some osteochondral defects heal on their own and never cause symptoms, while others become a chronic source of pain. When they do become symptomatic, the hallmark is deep, aching joint pain that worsens with weight bearing.⁷ You might notice swelling, stiffness, or a catching or locking sensation if a loose fragment is floating inside the joint. In the ankle, pain tends to be worst during push-off or when walking on uneven surfaces. In the knee, going up or down stairs and squatting are common triggers.

These symptoms overlap with many other joint problems, so clinical examination alone rarely clinches the diagnosis. A doctor will typically check for tenderness over the joint line, test range of motion, and look for effusion (fluid buildup). But the real diagnostic work happens on imaging.

How Osteochondral Defects Are Diagnosed

Standard X-rays can show larger bony abnormalities but often miss smaller or cartilage-only lesions. When an osteochondral defect is suspected and X-rays look normal, MRI is the go-to tool. It provides excellent visualization of both cartilage and bone, with sensitivity reaching about 96% and specificity between 96% and 100% for detecting talar lesions. MRI also demonstrates roughly 97% sensitivity and 100% specificity for identifying unstable lesions, the kind most likely to need surgery.⁸

One limitation of MRI is spatial resolution when dealing with very thin cartilage, as in the ankle. Standard 1.5-Tesla MRI scans sometimes struggle to distinguish fine details in these areas.⁹ In those situations, CT scans, MRI with joint contrast (arthrography), or higher-field-strength MRI can fill in the gaps. Arthroscopy, where a camera is inserted directly into the joint, remains the gold standard for evaluating the actual condition of the cartilage surface during surgery.

Once a defect is identified, clinicians grade its severity. The International Cartilage Repair Society (ICRS) system is one of the most widely used scales and has demonstrated good reliability between different observers, along with strong correlation to the true depth of damage confirmed on tissue samples.¹⁰ Grading matters because treatment decisions hinge on whether the defect is a shallow cartilage softening, a partial-thickness crack, a full-thickness cartilage loss, or a deep crater extending well into the bone.

Distinguishing Juvenile and Adult Lesions

Osteochondral defects in children and adolescents with open growth plates behave differently from those in adults. Younger patients have a substantially better chance of healing with conservative care, partly because their growing skeleton has a richer blood supply. But assessing stability on MRI is trickier in this age group. One study found that combining multiple MRI criteria achieved 100% sensitivity for detecting instability in both juvenile and adult lesions, but specificity dropped to just 11% in the juvenile group versus 100% in adults.¹¹ In practical terms, MRI in a child’s knee may flag a lot of false alarms for instability, so surgeons often weigh imaging findings alongside the child’s symptoms and age before recommending an operation.

Conservative Treatment

Not every osteochondral defect needs surgery. For smaller, stable lesions, especially in younger patients, a period of rest, activity modification, bracing, and sometimes a short stretch of reduced weight bearing can give the joint a chance to heal. Physical therapy focuses on maintaining range of motion and gradually rebuilding strength without overloading the healing surface.

The results, however, are uneven. A systematic review pooling data from over 860 patients with osteochondral lesions of the ankle found that conservative management achieved clinical success in roughly 45% of cases, with a median follow-up of about three years. Among those tracked with CT or MRI, focal deterioration of the lesion was seen in about 11 to 12% of patients, and progression to broader ankle osteoarthritis appeared in around 9%.¹² Those numbers suggest that conservative care works well enough for some people, but more than half may eventually need a surgical procedure. Close follow-up imaging is important so that a failing lesion can be caught before the surrounding joint pays the price.

Surgical Options

When conservative treatment falls short, the choice of surgery depends on the defect’s size, depth, location, and the patient’s activity goals. Surgeons generally move from less invasive to more invasive techniques as lesion severity increases.

Microfracture and Marrow Stimulation

Microfracture is often the first surgical step for smaller defects. The surgeon cleans out damaged tissue and then punches tiny holes into the exposed subchondral bone. Blood and marrow cells seep through those holes and form a clot that eventually matures into a repair tissue called fibrocartilage.¹³ The procedure is minimally invasive and can be done arthroscopically, which is a major advantage.

The catch is durability. Fibrocartilage is biochemically and mechanically inferior to the original hyaline cartilage. It tends to wear down over time, and long-term outcomes are variable, with some patients seeing their initial improvement erode around the four-year mark.^{14 15} For young, active patients or larger defects, microfracture is increasingly viewed as a bridge rather than a permanent solution.

Osteochondral Autograft Transfer (Mosaicplasty)

For moderate-sized defects, a surgeon can harvest one or more cylindrical plugs of healthy cartilage and bone from a low-load-bearing area of the same joint and press-fit them into the defect. Because these plugs carry intact hyaline cartilage attached to living bone, they provide immediate structural reconstruction.¹⁶

Compared with microfracture, osteochondral autograft transfer has shown better clinical results and a higher rate of return to sport, while microfracture patients trend toward more reoperations and deterioration over time. The trade-off: when autograft transfer was compared with autologous chondrocyte implantation (a cell-based therapy described below), the autograft group showed a higher failure rate at ten years of follow-up.¹⁷ A meta-analysis of single-stage cartilage procedures found that patients undergoing osteochondral autograft transfer showed substantial improvements in knee function and pain scores, with results tracked out to an average of about four and a half years.¹⁸

The main limitation is donor-site availability. You can only take so much cartilage from elsewhere in your own joint before creating new problems, which caps the defect size this technique can handle.

Osteochondral Allograft Transplantation

For large defects where an autograft would not cover enough ground, surgeons turn to donor tissue from a cadaver, called a fresh osteochondral allograft. A systematic review of long-term outcomes concluded that these allografts deliver good clinical and functional results, and that no other effective treatment currently exists for very large osteochondral lesions.¹⁹ Studies consistently show reliable improvement in pain and return to daily activities after the procedure.²⁰

Allografts must be transplanted fresh (typically within 28 days of harvest) to keep the cartilage cells alive, which creates logistical challenges around donor availability and timing. There is also a small risk of immune reaction and disease transmission, though screening protocols have made the latter extremely rare.

Cell-Based Therapies

Autologous chondrocyte implantation, or ACI, takes a different approach. In a first procedure, a small biopsy of your cartilage is harvested. The cells are grown in a lab over several weeks, then re-implanted into the defect during a second surgery. The more recent evolution, matrix-induced autologous chondrocyte implantation (MACI), seeds those lab-grown cells onto a scaffold membrane before implantation, which simplifies the surgical technique. MACI has been shown to produce hyaline-like cartilage, with biopsy studies demonstrating cartilage-like tissue forming as early as three weeks and about 75% hyaline-like regeneration by six months.²¹

Long-term data are encouraging. A systematic review found that ACI and MACI for knee cartilage lesions associated with osteoarthritis showed sustained success and allowed patients to delay or avoid joint replacement.²² A cost-effectiveness analysis in the German healthcare system found that MACI yielded improved quality of life compared with non-MACI treatment at a modest additional cost per quality-adjusted life year.²³ The drawbacks: the two-stage process, the weeks of lab culture, and the higher upfront expense compared with a one-step procedure like microfracture.

Rehabilitation After Surgery

Recovery from any osteochondral procedure is measured in months, not weeks, and the specifics depend heavily on what was done. Bracing is nearly universal in the early postoperative period. A review of published rehabilitation protocols found that the vast majority recommended immediate postoperative bracing following both autograft and allograft transplantation, with full weight bearing typically permitted around five to six weeks for autografts and about six weeks for allografts, though ranges varied considerably.²⁴

How aggressively weight bearing is progressed remains debated. Overly strict restrictions may actually harm the graft: prolonged non-weight-bearing can cause cartilage to lose protective molecules and deteriorate mechanically. Some surgeons, particularly those treating professional athletes, favor early limited weight bearing (around 20% of body weight in the first two weeks, progressing to full weight bearing afterward) when the graft is securely fixed, because it reduces muscle loss and allows earlier return to functional activities.²⁵ There is no universal protocol, so rehabilitation should be tailored to the specific surgery, graft stability, and the individual’s response.

Biomarkers and Predicting Who Will Respond

One of the frontiers in osteochondral defect management is figuring out, before surgery, which patients are most likely to do well. Researchers have been measuring inflammatory molecules in the synovial fluid (the liquid inside the joint) to see whether certain patterns predict outcomes. Elevated levels of specific inflammatory markers have been found to correlate strongly with more severe cartilage damage and with continued pain after surgery.²⁶

A separate study analyzing joint fluid proteins before microfracture surgery identified a combination of molecular markers, along with patient factors like smoking status, sex, and age, that could predict knee function scores a year later. Younger nonsmokers tended to fare better, but interestingly, specific protein levels in the joint fluid added predictive power beyond demographics alone.²⁷ This research is still early-stage, but the prospect of a joint-fluid test that helps match patients to the right procedure is genuinely exciting.

Tissue Engineering and Experimental Approaches

Because none of the current surgical options perfectly replicate the original osteochondral unit, considerable research is aimed at building replacement tissue from scratch. The core challenge is that the defect spans two very different materials: soft, slippery cartilage on top and rigid mineralized bone underneath, with a thin transitional zone between them. An ideal repair would restore all three layers.

Preclinical work on multiphasic scaffolds, structures with distinct layers designed to mimic cartilage and bone, has shown favorable results in animal models, with simultaneous regeneration of both tissue types.²⁸ These scaffolds typically use softer hydrogels for the cartilage layer and stiffer ceramics or mineral-containing materials for the bone layer.²⁹ Triphasic designs that add a distinct interface layer are also being explored.³⁰

Mesenchymal stem cells, often delivered via a bone marrow aspirate concentrate, offer another experimental avenue. Results so far have been mixed. A review of patients treated with bone marrow concentrate for ankle lesions found that clinical scores improved at an average of nearly three years, but MRI at four years revealed incomplete filling of the defect in over half of patients.³¹ Animal studies combining stem cells with injectable synthetic scaffolds have shown more promising integration, but these remain preclinical.³²

Lessons from Veterinary Medicine

Horses suffer from osteochondritis dissecans at high rates, and the equine joint is large enough to closely approximate the biomechanics of a human knee or ankle. The horse model is already widely accepted by the scientific community and regulators for developing and testing cellular therapies intended for eventual human use.³³ Successful repair of large bilateral osteochondral lesions in a horse using a multilayered tissue-engineered construct has already been demonstrated, pointing toward clinical translation for human patients.³⁴ Much of the scaffold and stem-cell work described above was first tested in equine or other large-animal joints before moving toward human trials, a pipeline that continues to accelerate.